Adam Brufsky, MD, PhD, FACP, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer.
Adam Brufsky, MD, PhD, FACP, professor of medicine, associate division chief, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer (TNBC).
Clinical Pearls:
The tnAcity trial will measure the efficacy of combinations, such as gemcitabine and carboplatin, carboplatin and nab-paclitaxel (Abraxane), and gemcitabine and nab-paclitaxel
During this phase II trial, which has about 80 patients enrolled, patients will be randomized to receive one of the three combinations
Based on the results of the phase II trial, the two combinations that prove to be the most effective will be tested further
The trial will also investigate biomarkers that will help physicians figure out how to optimally treat patients with TNBC
